Merger lifts Liminatus Pharma equity above $2.5M, but Nasdaq compliance decision still pending
LIMN is trading near its 52-week low of $0.095 (13% above the low) on light trading volume (0.1× avg).
Summary
Liminatus Pharma disclosed that its merger with InnocsAI has lifted stockholders' equity above $2.5 million, a level that could satisfy Nasdaq's continued listing requirement. The company awaits Nasdaq's decision, but warns that future compliance will be monitored.
Key Events · Corporate Governance and Compliance · LIMN
-
Equity Exceeds $2.5M Threshold
As a result of the InnocsAI merger, the company believes its stockholders' equity now exceeds $2.5 million, a key Nasdaq continued listing requirement.
-
Nasdaq Compliance Decision Pending
The company is waiting for Nasdaq to determine if it is in compliance; even if compliant, Nasdaq will monitor ongoing compliance in future periodic reports.
-
Delisting Risk Remains
Despite the equity improvement, the company may face future delisting if it fails to evidence compliance at the time of its next periodic report.
-
Follows Denied Extension
This update comes six days after Nasdaq denied a second 180-day extension to regain compliance, heightening the urgency of the equity threshold.
Analysis · LIMN · Life Sciences
The merger with InnocsAI has boosted stockholders' equity above $2.5 million, a key threshold for Nasdaq listing compliance. While this is a positive step, the company is still awaiting a formal determination from Nasdaq, and even if compliant now, ongoing monitoring means delisting risk persists. This update comes just days after Nasdaq denied a second extension, making the equity figure a critical data point for survival.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LIMN was trading at $0.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $0.10 to $8.06. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.